Servier loses case over Mediator issues; Merck discounts Remicade in U.K. to fend off biosimilars;

@FiercePharma: Asia's dengue epidemic highlights race for treatment, vaccine options. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Japan's says its mAb work with means a need for a $309M API plant expansion. FiercePharmaManufacturing news | Follow @EricPFierce

@CarlyHFierce: : We did an episode of @FierceBiotech Radio on biopharma's wacky Wednesday. More | Follow @CarlyHFierce

> Merck ($MRK), which sells arthritis treatment Remicade in the EU, has discounted the drug 25% in the U.K., in the face of biosimilar competition that has scarfed up market share in Europe. Story

> French drugmaker Servier has been found negligent in a civil case in France for not pulling more quickly from the market its diabetes drug Mediator which was tied to heart issues and 2,100 deaths. Story

> Recruitment is underway for the 130 jobs Pfizer ($PFE) will create in Ireland. More

> The U.K. price watchdog in final guidance recommended Bristol-Myers Squibb's ($BMY) Orencia, AbbVie's ($ABBV) Humira, Pfizer's Enbrel and Roche's ($RHHBY) RoActemra for treating juvenile idiopathic arthritis. Report

> India's Strides Arcolab has bought a portfolio of 7 drugs from Johnson & Johnson ($JNJ) in India. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Roche notches molecular diagnostics sales win; Veracyte CEO lambastes CMS pricing proposals. Report | Follow @EmilyWFierce

> Congressman to introduce bill banning Bayer's Essure contraceptive device. More

> Swiss scientists reveal miniaturized patient monitoring device for ICU. Story

Biotech News

@FierceBiotech: Merrimack wins expedited FDA OK for pancreatic cancer drug Onivyde. Report | Follow @FierceBiotech

@JohnCFierce: The $NK market cap is down to a meager $873M, debuted at $2.6B -- Still too much? Soon-Shiong magic sparkles not so shiny? | Follow @JohnCFierce

@DamianFierce: So I guess $SHPG's Lumena buyout didn't go so well. Story | More | Follow @DamianFierce

> Amgen's T-Vec inches toward EU approval for melanoma. Report

> Spectrum tanks after the FDA rejects its blood cancer drug. Article

And Finally... Animal testing in U.K. labs has fallen to 6%. More

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.